Drugs / Daratumumab
Daratumumab
also known as
Darzalex · DARA · DARZALEX FASPRO · Dara-SC · Daratumumab and Recombinant Human Hyaluronidase · Daratumumab-hyaluronidase · Daratumumab-Hyaluronidase-Fihj · JNJ-54767414 · +6 more
Monoclonal antibody targets CD38
Regulatory milestones approvals, filings & regulatory actions · 23 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (8) | US (FDA) | DARZALEX FASPRO | — | 2021-01-11 – 2026-01-27 | fda.gov ↗ |
| Label expansions (13) | US (FDA) | DARZALEX | — | 2016-11-21 – 2025-04-10 | fda.gov ↗ |
| Approved | EU (EMA) | Darzalex | — | 2016-05-20 | europa.eu ↗ |
| Approved | US (FDA) | DARZALEX | — | 2015-11-16 | fda.gov ↗ |
Trials 267 · started per year
today
US approved 2015
EU approved 2016
1
4
1
7
10
10
28
31
31
19
30
17
25
16
18
17
200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT07026604 | Jul 2025 → Jul 2026 overdue | famililal cerebral cavernous malformations | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06142396 | Nov 2024 → Nov 2027 expected | kidney failure, plasma cell myeloma | Augusta University | Recruiting | No outcome recorded |
| Phase 0 | NCT06398457 | Sep 2024 → Sep 2026 expected | Hodgkins lymphoma, acute myeloid leukemia, adult acute lymphoblastic leukemia, aplastic anemia +5 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 0 | NCT04139304 | May 2021 → Jul 2029 expected | plasmablastic lymphoma | AIDS Malignancy Consortium | Recruiting | No outcome recorded |
| Phase 0 | NCT03473730 | May 2018 → Jan 2025 | clear cell renal carcinoma, urothelial carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 136 trials | ||||||
| Phase 1 | NCT07341867 | Aug 2026 → Mar 2028 expected | plasma cell myeloma, triple-negative breast carcinoma | Andrew Hantel, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07513129 | Jun 2026 → Dec 2029 expected | T-cell acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05749276 | Feb 2025 → Aug 2028 expected | acute myeloid leukemia | Nantes University Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05832216 | Apr 2023 → Oct 2024 | aplastic anemia, blood platelet disease | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase 1 | NCT05641324 | Feb → Jul 2023 | plasma cell myeloma | Anaveon AG | Terminated | No outcome recorded |
| Phase 1 | NCT05556616 | Jan 2023 → Jun 2024 | plasma cell myeloma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT05137054 | Aug 2022 → Mar 2028 expected | plasma cell myeloma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT05004259 | Mar 2022 → Sep 2024 | hemolytic anemia | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT04895410 | Jan → Jun 2022 | plasma cell myeloma | AbbVie | Terminated | No outcome recorded |
| Phase 1 | NCT04667663 | Dec 2021 → Apr 2022 overdue | plasma cell myeloma | Cancer Trials Ireland | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05182073 | Nov 2021 → Sep 2024 | plasma cell myeloma | Fate Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05050097 | Sep 2021 → Mar 2025 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04610320 | Jul 2021 → Jan 2024 | anti-HLA hyperimmunization, transplant rejection | Ronald Witteles | Completed | No outcome recorded |
| Phase 1 | NCT04892264 | Jun 2021 → Mar 2024 | plasma cell myeloma | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT04088903 | Apr 2021 → Apr 2023 | anti-HLA hyperimmunization, transplant rejection | Ronald Witteles | Withdrawn | No outcome recorded |
| Phase 1 | NCT04614636 | Oct 2020 → Jul 2023 | acute myeloid leukemia, plasma cell myeloma | Fate Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT04108195 | Feb 2020 → Apr 2027 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04121260 | Dec 2019 → Apr 2021 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04136756 | Oct 2019 → Apr 2023 | non-Hodgkin lymphoma, plasma cell myeloma | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04045028 | Jul 2019 → Mar 2023 | non-Hodgkin lymphoma, plasma cell myeloma | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03447808 | Aug 2018 → May 2026 | B-cell chronic lymphocytic leukemia | Jennifer Woyach | Completed | No outcome recorded |
| Phase 1 | NCT03432741 | Mar 2018 → Aug 2022 | Hodgkins lymphoma, breast adenocarcinoma, mycosis fungoides, nodal marginal zone B-cell lymphoma | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT03311828 | Feb 2018 → Jan 2020 | AA amyloidosis, plasma cell myeloma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03283917 | Feb 2018 → Jun 2026 | AL amyloidosis | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03320707 | Oct 2017 → Aug 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03242889 | Aug → Nov 2017 | plasma cell myeloma | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT03068351 | Jun 2017 → Aug 2019 | plasma cell myeloma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03177460 | Jun 2017 → Jan 2024 | prostate adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02955810 | Nov 2016 → Sep 2018 | plasma cell myeloma | National University of Ireland, Galway, Ireland | Unknown | No outcome recorded |
| Phase 1 | NCT02852837 | Sep 2016 → Dec 2019 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02918331 | Sep 2016 → Oct 2017 | plasma cell myeloma | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT02519452 | Oct 2015 → Dec 2017 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02431208 | Jul 2015 → Mar 2021 | plasma cell myeloma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02497378 | Jul 2015 → Mar 2018 | plasma cell myeloma | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT02116569 | Apr 2014 → Sep 2015 | plasma cell myeloma | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT01998971 | Feb 2014 → Jan 2019 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1/231 trials | ||||||
| Phase 1/2 | NCT07681596 | Jul 2026 → Oct 2029 expected | refractory plasma cell neoplasm | AstraZeneca | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07287228 | Dec 2025 → Dec 2027 expected | aplastic anemia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07110662 | Oct 2025 → Oct 2028 expected | severe cutaneous adverse reaction, toxic epidermal necrolysis | Hospices Civils de Lyon | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07075510 | Oct 2025 → Oct 2030 expected | plasma cell neoplasm | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07099391 | Jul 2025 → Jul 2029 expected | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06892522 | Jun 2025 → Feb 2036 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06785415 | Mar 2025 → Apr 2031 expected | plasma cell myeloma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05486481 | Jan 2024 → Dec 2028 | AL amyloidosis | Alfred Chung, MD | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06055075 | Dec 2023 → Jul 2025 | refractory plasma cell neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT06119685 | Oct 2023 → Dec 2025 overdue | non-Hodgkin lymphoma, plasma cell myeloma | Indapta Therapeutics, INC. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05671757 | May 2023 → Jun 2026 overdue | autoimmune disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05857982 | May 2023 → Jan 2025 | refractory plasma cell neoplasm | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05434689 | Jan 2023 → Aug 2028 expected | plasma cell myeloma | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04922723 | Oct 2022 → Dec 2026 expected | glioblastoma | West Virginia University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05408026 | Oct 2022 → Oct 2025 | refractory plasma cell neoplasm | Alliance Foundation Trials, LLC. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04827979 | Nov 2021 → Mar 2027 expected | anti-HLA hyperimmunization | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04973605 | Sep 2021 → Nov 2026 expected | refractory plasma cell neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04204980 | Feb 2020 → Jun 2023 | anti-HLA hyperimmunization, transplant rejection | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1/2 | NCT03537599 | Jan 2020 → Aug 2021 | acute myeloid leukemia with multilineage dysplasia, childhood acute myeloid leukemia | Sumithira Vasu | Terminated | No outcome recorded |
| Phase 1/2 | NCT03837509 | Sep 2019 → Apr 2022 | refractory plasma cell neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT03732703 | Apr 2019 → Dec 2024 | refractory plasma cell neoplasm | Multiple Myeloma Research Consortium | Completed | No outcome recorded |
| Phase 1/2 | NCT03481556 | Apr 2018 → Feb 2022 | plasma cell myeloma | Oncopeptides AB | Terminated | No outcome recorded |
| Phase 1/2 | NCT03098550 | Jun 2017 → Jul 2020 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT02841033 | Mar 2017 → May 2020 | AL amyloidosis | Boston Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03023423 | Dec 2016 → May 2018 | non-small cell lung carcinoma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT02773030 | Oct 2016 → May 2024 overdue | plasma cell myeloma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02488759 | Oct 2015 → Mar 2021 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT02343042 | Oct 2015 → Apr 2027 expected | plasma cell myeloma | Karyopharm Therapeutics Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01665794 | Aug 2012 → Nov 2025 | plasma cell myeloma | University of Chicago | Completed | No outcome recorded |
| Phase 1/2 | NCT01592370 | Aug 2012 → Sep 2020 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT01615029 | Jun 2012 → Oct 2015 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2146 trials | ||||||
| Phase 2 | NCT07247097 | Aug 2026 → Dec 2030 expected | plasma cell myeloma | Massachusetts General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07605416 | Jul 2026 → Nov 2032 expected | plasma cell leukemia | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07029776 | Jul 2026 → Apr 2030 expected | plasma cell myeloma | University of Arkansas | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06348147 | Jul 2026 → May 2027 | disease related to hematopoietic stem cell transplant, plasma cell myeloma | UNC Lineberger Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT07638683 | May 2026 → Jul 2028 expected | AL amyloidosis, plasma cell myeloma | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07485647 | May 2026 → May 2028 expected | plasma cell myeloma | Eden Biltibo | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07362238 | Mar 2026 → Mar 2028 expected | autoimmune thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07362199 | Mar 2026 → Mar 2027 expected | autoimmune thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07234019 | Jan 2026 → Nov 2028 expected | autoimmune thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07297563 | Jan 2026 → Nov 2027 expected | autoimmune thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Show all 146 trials opens the full record — a long page | ||||||
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT05403138 | Nov 2022 → Nov 2025 overdue | neuromyelitis optica spectrum disorder with anti-AQP4 antibodies | Tianjin Medical University General Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04513639 | Aug 2020 → Jun 2031 expected | plasma cell myeloma | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03357952 | Nov 2017 → Oct 2018 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2/3 | NCT02419118 | Jan → Oct 2015 | plasma cell myeloma | Vejle Hospital | Completed | No outcome recorded |
| Phase 330 trials | ||||||
| Phase 3 | NCT07649525 | Jul 2026 → Jun 2033 expected | plasma cell leukemia, plasma cell myeloma | University of Leeds | Recruiting | No outcome recorded |
| Phase 3 | NCT07222761 | Jan 2026 → May 2029 expected | refractory plasma cell neoplasm | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06918002 | Jul 2025 → May 2036 expected | plasma cell myeloma | Intergroupe Francophone du Myelome | Recruiting | No outcome recorded |
| Phase 3 | NCT06867991 | Nov 2024 → Nov 2026 expected | anti-NMDA receptor encephalitis | The First People's Hospital of Changzhou | Recruiting | No outcome recorded |
| Phase 3 | NCT06187441 | May 2024 → Jan 2031 expected | plasma cell myeloma | HOVON Foundation | Recruiting | No outcome recorded |
| Phase 3 | NCT05438043 | Dec 2022 → Jan 2029 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT05020236 | Oct 2021 → Apr 2026 overdue | plasma cell myeloma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT04649060 | Dec 2020 → Feb 2022 | plasma cell myeloma, refractory plasma cell neoplasm | Oncopeptides AB | Terminated | No outcome recorded |
| Phase 3 | NCT04181827 | Jun 2020 → May 2024 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03993912 | Oct 2019 → Oct 2026 expected | plasma cell myeloma | University Hospital, Lille | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03937635 | Sep 2019 → Dec 2029 expected | smoldering plasma cell myeloma | ECOG-ACRIN Cancer Research Group | Recruiting | No outcome recorded |
| Phase 3 | NCT04071457 | Aug 2019 → Jul 2029 expected | plasma cell myeloma | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03836014 | Jul 2019 → Jul 2026 overdue | plasma cell myeloma | Assistance Publique - Hôpitaux de Paris | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03901963 | Apr 2019 → Apr 2024 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03651128 | Apr 2019 → Apr 2026 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03710603 | Dec 2018 → Aug 2023 overdue | plasma cell myeloma | Stichting European Myeloma Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03792620 | Nov 2018 → May 2020 | plasma cell myeloma | Grupo de Estudos Multicentricos em Onco-Hematologia | Unknown | No outcome recorded |
| Phase 3 | NCT03652064 | Nov 2018 → May 2024 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03742297 | Oct 2018 → Jul 2023 overdue | plasma cell myeloma | PETHEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03234972 | Nov 2017 → Oct 2019 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03217812 | Nov 2017 → Jul 2020 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03301220 | Nov 2017 → May 2024 | smoldering plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03277105 | Oct 2017 → Jun 2019 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03201965 | Oct 2017 → Feb 2020 | amyloidosis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03180736 | Jun 2017 → Jul 2020 | plasma cell myeloma | Stichting European Myeloma Network | Completed | No outcome recorded |
| Phase 3 | NCT03158688 | Jun 2017 → Jul 2019 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT02541383 | Sep 2015 → Aug 2020 | plasma cell myeloma | Intergroupe Francophone du Myelome | Completed | No outcome recorded |
| Phase 3 | NCT02195479 | Dec 2014 → Nov 2017 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02136134 | Aug 2014 → Jan 2016 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02076009 | Jul 2014 → Mar 2016 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT07191379 | Aug 2026 → Jun 2027 expected | plasma cell myeloma | Odense University Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07274462 | Nov 2025 → Mar 2027 expected | vasculitis | University Hospital, Martin | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06409702 | Jun 2024 → Nov 2027 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 4 | NCT05888870 | Nov 2023 → Dec 2026 expected | hemophilia A | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 4 | NCT05849740 | May 2023 → Apr 2027 expected | acquired hemophilia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 4 | NCT05511428 | Nov 2022 → May 2024 | plasma cell myeloma | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 4 | NCT03829371 | Jan 2019 → Jan 2027 expected | plasma cell myeloma | University of Turin, Italy | Active not recruiting | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT06697483 | Dec 2024 → Dec 2026 expected | plasma cell myeloma | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT06455748 | Mar 2024 → Jan 2025 | AL amyloidosis | Yongyong MA | Unknown | No outcome recorded |
| — | NCT05913596 | May 2023 → Apr 2024 | transplant rejection | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| — | NCT06376214 | Jan 2023 → Dec 2025 overdue | AL amyloidosis | Nanjing University School of Medicine | Recruiting | No outcome recorded |
| — | NCT06571864 | Jan 2022 → Jan 2024 | AL amyloidosis | University of Turin, Italy | Completed | No outcome recorded |
| — | NCT05088330 | Dec 2021 → May 2023 | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT04264884 | — | — | Janssen Research & Development, LLC | Approved for marketing | No outcome recorded |
| — | NCT02477891 | — | plasma cell myeloma | Janssen Research & Development, LLC | Approved for marketing | No outcome recorded |
Also used as a comparator or background therapy in 87 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 120 trials | ||||||
| Phase 1 | NCT07221032 Background | Jul 2026 → Mar 2028 expected | plasma cell myeloma | Medical College of Wisconsin | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07082270 Background | Apr 2026 → Feb 2028 | plasma cell myeloma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT07400744 Comparator | Mar → Sep 2026 expected | plasma cell myeloma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06287944 Background | Jul 2025 → May 2028 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06622005 Background | Apr 2025 → Apr 2027 expected | plasma cell myeloma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT06768489 Background | Dec 2024 → Jan 2029 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06371534 Comparator | Apr 2024 → Apr 2025 | neoplasm | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06042725 Background | Mar 2024 → Dec 2028 expected | plasma cell myeloma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT05974969 Comparator | May → Aug 2023 | — | Biocad | Completed | No outcome recorded |
| Phase 1 | NCT05679258 Comparator | Jan 2023 → Mar 2024 | plasma cell myeloma | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 1 | NCT05363111 Background | Nov 2022 → Mar 2027 expected | plasma cell myeloma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05259839 Background | Oct 2022 → Sep 2033 expected | refractory plasma cell neoplasm | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05308654 Background | May 2022 → Feb 2024 overdue | refractory plasma cell neoplasm | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05243342 Background | Apr 2022 → Jul 2024 | plasma cell myeloma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04714372 Background | Nov 2021 → Jan 2024 | acute myeloid leukemia, monocytic leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT05139225 Background | Oct 2021 → Jul 2026 | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT04910568 Background | Jul 2021 → Dec 2028 expected | plasma cell myeloma | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04722146 Background | Mar 2021 → Oct 2025 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04280328 Background | Feb 2020 → Sep 2021 | plasma cell myeloma | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03591744 Background | Oct 2018 → Oct 2019 | plasma cell leukemia | City of Hope Medical Center | Withdrawn | No outcome recorded |
| Phase 1/212 trials | ||||||
| Phase 1/2 | NCT06953960 Background | Jul 2025 → Dec 2030 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05590377 Background | Jan 2023 → May 2024 | plasma cell myeloma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT05451771 Comparator | Oct 2022 → Sep 2027 expected | AL amyloidosis | Columbia University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05581875 Background | Oct 2022 → Oct 2026 expected | corneal disorder, monoclonal paraproteinemia disease, plasma cell myeloma | Hellenic Society of Hematology | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05392946 Background | Aug 2022 → Sep 2026 expected | plasma cell myeloma | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05280275 Background | Apr 2022 → Mar 2026 | corneal disorder, monoclonal paraproteinemia disease, plasma cell myeloma | Hellenic Society of Hematology | Unknown | No outcome recorded |
| Phase 1/2 | NCT04942067 Background | Dec 2021 → Sep 2024 | amyloidosis, plasma cell myeloma | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05205252 Comparator | Dec 2021 → Jul 2023 | refractory hematologic cancer | Epizyme, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04824794 Comparator | Mar 2021 → Jun 2025 | acute myeloid leukemia, diffuse large B-cell lymphoma, refractory plasma cell neoplasm | Genmab | Terminated | No outcome recorded |
| Phase 1/2 | NCT03989414 Background | Sep 2019 → Nov 2026 expected | plasma cell myeloma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04068597 Background | Aug 2019 → Mar 2027 expected | T-cell non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | CellCentric Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03701321 Background | Jan 2019 → May 2020 | plasma cell myeloma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 220 trials | ||||||
| Phase 2 | NCT06948084 Background | Aug 2026 → Feb 2028 expected | plasma cell myeloma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07149857 Background | Oct 2025 → Apr 2028 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06974786 Background | Aug 2025 → Nov 2032 expected | plasma cell myeloma | SCRI Development Innovations, LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT07045909 Background | Jun 2025 → Mar 2028 expected | plasma cell myeloma | PETHEMA Foundation | Recruiting | No outcome recorded |
| Phase 2 | NCT06931704 Comparator | May 2025 → Nov 2030 expected | plasma cell myeloma | Nantes University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06577025 Background | Aug 2024 → Sep 2030 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06169215 Background | Jul 2024 → Sep 2026 expected | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06353022 Background | Jun 2024 → Apr 2028 expected | plasma cell myeloma | Nantes University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05896228 Background | Feb 2024 → Mar 2029 expected | plasma cell myeloma | Benjamin T Diamond, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT06889948 Comparator | Jan 2024 → Jun 2027 expected | glomerulonephritis, kidney failure, monoclonal paraproteinemia disease | Helsinki University Central Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05231629 Background | Dec 2023 → Dec 2027 expected | plasma cell myeloma | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 2 | NCT04756401 Background | Dec 2022 → Sep 2024 overdue | plasma cell myeloma | Academic and Community Cancer Research United | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05695508 Background | Dec 2022 → Sep 2028 expected | plasma cell myeloma | University of Heidelberg Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04223661 Background | Dec 2021 → Dec 2022 | plasma cell myeloma | Attaya Suvannasankha | Withdrawn | No outcome recorded |
| Phase 2 | NCT04205240 Background | Dec 2020 → May 2021 | plasma cell myeloma | Srinivas Devarakonda | Terminated | No outcome recorded |
| Phase 2 | NCT04407442 Background | Nov 2020 → Apr 2023 | plasma cell myeloma | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 2 | NCT04304144 Background | Mar 2020 → Nov 2023 | AL amyloidosis | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04133636 Background | Nov 2019 → Feb 2027 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03314181 Background | Apr 2018 → May 2031 expected | plasma cell myeloma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03215524 Background | Oct 2017 → Jun 2022 | plasma cell myeloma | Canadian Myeloma Research Group | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07428369 Comparator | Jun 2026 → May 2038 | plasma cell myeloma | Regeneron Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT07095452 Background | Jan 2026 → Jan 2042 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 331 trials | ||||||
| Phase 3 | NCT07709715 Comparator | Jan 2027 → Dec 2028 expected | AL amyloidosis | Nexcella Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07665450 Background | Sep 2026 → Sep 2030 expected | plasma cell myeloma | Janssen Research & Development, LLC | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07285239 Comparator | Jul 2026 → Nov 2031 expected | plasma cell myeloma | PrECOG, LLC. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07671287 Background | Jun 2026 → Feb 2031 expected | plasma cell myeloma | University of Heidelberg Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07555938 Comparator | Jun 2026 → Oct 2028 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT07623798 Comparator | Jun 2026 → May 2029 expected | refractory plasma cell neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07393282 Comparator | May 2026 → Jul 2033 expected | smoldering plasma cell myeloma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07452198 Comparator | Mar 2026 → Mar 2029 expected | plasma cell myeloma | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07391657 Comparator | Feb 2026 → Jun 2028 expected | refractory plasma cell neoplasm | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06932562 Background | Dec 2025 → Dec 2036 expected | plasma cell myeloma | European Myeloma Network B.V. | Recruiting | No outcome recorded |
| Phase 3 | NCT06952478 Comparator | Aug 2025 → Nov 2027 expected | refractory plasma cell neoplasm | Celltrion | Recruiting | No outcome recorded |
| Phase 3 | NCT06895512 Comparator | Apr 2025 → Jul 2027 expected | plasma cell myeloma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06615479 Background | Mar 2025 → Dec 2027 expected | refractory plasma cell neoplasm | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06742138 Comparator | Jan 2025 → Dec 2027 expected | plasma cell myeloma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06679101 Comparator | Dec 2024 → Apr 2031 expected | plasma cell myeloma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06413498 Comparator | Aug 2024 → Jul 2028 expected | plasma cell myeloma | Kite, A Gilead Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06232707 Comparator | May 2024 → Nov 2025 | plasma cell myeloma | Celgene Corporation | Withdrawn | No outcome recorded |
| Phase 3 | NCT06182774 Comparator | Apr 2024 → Jan 2032 expected | plasma cell myeloma | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 3 | NCT06464991 Comparator | Mar 2024 → Aug 2027 expected | plasma cell myeloma | Nanjing IASO Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05257083 Background | Oct 2023 → Jun 2033 expected | plasma cell myeloma | Stichting European Myeloma Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05776940 Comparator | Mar 2023 → Mar 2026 | AL amyloidosis | Air Force Military Medical University, China | Unknown | No outcome recorded |
| Phase 3 | NCT05675319 Comparator | Mar 2023 → Mar 2025 | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Terminated | No outcome recorded |
| Phase 3 | NCT05623020 Background | Nov 2022 → Oct 2030 expected | plasma cell myeloma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT05552222 Background | Oct 2022 → Apr 2031 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT05455320 Background | Oct 2022 → Jul 2027 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04975997 Comparator | Jun 2022 → Nov 2027 expected | plasma cell myeloma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06868654 Comparator | Jul 2021 → Apr 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06868667 Comparator | Jul 2021 → Apr 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04246047 Comparator | May 2020 → Oct 2023 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04288765 Background | Mar 2020 → Dec 2024 | plasma cell myeloma | Grupo Cooperativo de Hemopatías Malignas | Withdrawn | No outcome recorded |
| Phase 3 | NCT02252172 Comparator | Feb 2015 → Sep 2018 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07081126 Comparator | Jul 2025 → Jul 2026 overdue | acute transplant rejection | University Hospital, Martin | Recruiting | No outcome recorded |
| — | NCT06192979 Background | Jan 2024 → Sep 2026 expected | primary systemic amyloidosis | Jin Lu, MD | Recruiting | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-12-01 | Amgen | FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse amgen.com ↗ |
| 2020-08-20 | Amgen | FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens amgen.com ↗ |
| 2019-12-10 | Amgen | Amgen Data From Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting amgen.com ↗ |
| 2019-09-13 | Amgen | Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival amgen.com ↗ |
| 2016-11-10 | Amgen | Amgen Announces Collaboration With Janssen To Co-Fund Studies With KYPROLIS® (Carfilzomib) And DARZALEX® (Daratumumab) In Patients With Multiple Myeloma amgen.com ↗ |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 360 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | daratumumab | “APG-2575+ Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone will be administered at a dose of 40 mg (or 20 mg...” NCT04942067 ↗341“The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab,...” NCT07099391 ↗ “The purpose of this study is to evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment...” NCT07709715 ↗ “Induction therapy consist of bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab, lenalidomide, and dexamethasone (DRd) or daratumumab, bortezomib, lenalidomide,...” NCT07149857 ↗ “Anti-CD38 Monoclonal Antibody: Daratumumab is intravenously given at the dose of 16 mg/kg weekly for 8 weeks, then every two weeks for 8 more times, and lastly monthly until...” NCT06571864 ↗ “Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7...” NCT03215524 ↗ “Daratumumab and Dexamethasone Combined With Pomalidomide (DPD) or ASCT in the Treatment of Newly Diagnosed Systemic Light Chain Amyloidosis (AL Amyloidosis): a Prospective,...” NCT06376214 ↗ “induction therapy using the combination of dexamethasone, lenalidomide (revlimid), daratumumab (Darzalex) and carfilzomib (Kyprolis) to treat patients with newly diagnosed...” NCT03224507 ↗ “Daratumumab, a human IgG monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action, has been approved to treat patients with multiple...” PMID 37022569 ↗ Apr 2023 “Phase II Clinical Study of Daratumumab Combined With Bortezomib, Lenalidomide and Dexamethasone (DVRd) in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma” NCT06158269 ↗ “The therapeutic monoclonal antibody (t-mAb) daratumumab, used to treat multiple myeloma (MM) patients, interferes with routine, electrophoretic based M-protein diagnostics.” PMID 34392637 ↗ Aug 2021 “The primary objective is to assess the efficacy and safety of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (Dara-VRD) followed by cilta-cel in high-risk SMM.” NCT06574126 ↗ “Daratumumab is a human IgG1 mAb that binds with high affinity to unique epitope on cluster of differentiation 38 (CD38) and attacks tumor cells that overexpress CD38.” NCT03871829 ↗ “compare the PK characteristics, safety, tolerability, and immunogenicity of HLX15 and daratumumab infusion (DARZALEX®, CN-sourced) in healthy Chinese male subjects.” NCT05679258 ↗ “Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle” NCT04975997 ↗ “Patient will receive Dara-CyBorD (Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone) for at least 6 cycles, and then Daratumumab maintainance.” NCT06418477 ↗ “Therefore, the use of daratumumab to clear APS with secondary thrombocytopenia may be effective and represents a new therapeutic strategy.” NCT05983952 ↗ “daratumumab-KRd (D-KRd; daratumumab 16 mg/kg intravenous weekly [cycles 1-2], biweekly [cycles 3-6], and every 4 weeks [cycles 7-18])” PMID 40769684 ↗ Aug 2025 “Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone” NCT05231629 ↗ “subcutaneous daratumumab (1800 mg on days 1, 8, 15, 22 of cycles 1-2 and days 1, 15 for cycles 3-6)” NCT04991103 ↗ “Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma” NCT03346135 ↗ “DARZALEX® = Daratumumab. Solution for injection, 1800 mg/15 mL, single vial.” NCT05749276 ↗ “treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.” NCT06771180 ↗ “Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma” NCT04065308 ↗ “-Subcutaneous daratumumab and hyaluronidase-fihj” NCT04150692 ↗ “Daratumumab 16mg/kg, days 1, 8, 15” NCT03188172 ↗ “Drug: Daratumumab/rHuPH20” NCT04045028 ↗ “Biological: Daratumumab” NCT04895410 ↗ “Drug: Daratumumab” NCT04614636 ↗ “Drug: Daratumumab” NCT06953960 ↗ “Daratumumab” NCT04892264 ↗ “Daratumumab” NCT04230031 ↗ “Daratumumab” NCT04756401 ↗ |
| Known as | 3003-005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743007 ↗ |
| Known as | CT-P44 | “Biological: CT-P44(Daratumumab)” NCT06952478 ↗ |
| Known as | DARA | “This phase 1b study (NCT02431208) evaluated the safety and efficacy of the anti-programmed death-ligand 1 monoclonal antibody atezolizumab (Atezo) alone or in combination with...” PMID 37559718 ↗ Jul 20234“This trial investigates the use of Daratumumab (DARA), an antibody directed at the human cluster of differentiation 38 (CD38) molecule, for the treatment of patients with...” NCT04396496 ↗ “Daratumumab (DARA) has shown impressive activity in combination with other agents for the treatment of multiple myeloma (MM).” PMID 31201169 ↗ Jun 2019 “Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (dex) (DPd)” NCT03651128 ↗ “Daratumumab (Dara)” NCT03829371 ↗ |
| Known as | Dara IV | “Participants will receive daratumumab for intravenous infusion (Dara IV) 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks on Day 1 in Cycle 7...” NCT03277105 ↗ |
| Known as | Dara-SC | “Participants will receive a fixed dose of daratumumab as 1800 milligram (mg) subcutaneously (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Unit per...” NCT03277105 ↗1“daratumumab subcutaneous (Dara-SC)” NCT03871829 ↗ |
| Known as | Daratumumab and Recombinant Human Hyaluronidase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07082270 ↗ |
| Known as | Daratumumab component of darzalex faspro | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743007 ↗ |
| Known as | Daratumumab-fihj | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743007 ↗ |
| Known as | Daratumumab-hyaluronidase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07085728 ↗ |
| Known as | Daratumumab-Hyaluronidase-Fihj | “Drug: Daratumumab Hyaluronidase-fihj” NCT05139225 ↗ |
| Known as | Darzalex | “Daratumumab has been approved by the U.S. Food and Drug Administration (FDA) alone or in combination with other standard of care drugs for treatment of multiple myeloma in both...” NCT07075510 ↗11“DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma” NCT06895512 ↗ “KRdD = Kyprolis (Carfilzomib), Revlimid (Lenalidomide), dexamethasone, Darzalex (Daratumumab)” NCT03224507 ↗ “after receiving Darzalex (daratumumab) and then have a prostatectomy” NCT03035357 ↗ “has been approved since 2016 under the trade name Darzalex®” NCT04810754 ↗ “Daratumumab SC (Darzalex)” NCT06918002 ↗ “DARATUMUMAB (DARZALEX®)” NCT07274462 ↗ “DARATUMUMAB (DARZALEX®)” NCT07110662 ↗ |
| Known as | DARZALEX FASPRO | “Daratumumab has been approved by the U.S. Food and Drug Administration (FDA) alone or in combination with other standard of care drugs for treatment of multiple myeloma in both...” NCT07075510 ↗4“Dratumumab / Hyaluronidase Injection [Darzalex Faspro]” NCT06376214 ↗ “Biological: Darzalex Faspro(Daratumumab)” NCT06952478 ↗ |
| Known as | HUMAX-CD 38 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743007 ↗ |
| Known as | JNJ-54767414 | “JNJ-54767414 (Daratumumab) will be administered as an Intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, on Day 1 of Cycles...” NCT02497378 ↗1“A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible...” NCT02918331 ↗ |
| Action | Deplete | “elimination of CD38+ T cells” PMID 32928795 ↗ Sep 2020 |
| Modality | Monoclonal antibody | “Daratumumab is a CD38-targeted human monoclonal antibody” PMID 30536810 ↗ Dec 2018 |
| Route | Intravenous | “patients were given intravenous daratumumab 16 mg/kg” PMID 32470437 ↗ Jun 2020 |
| Target | CD38 | “Daratumumab is a CD38-targeted human monoclonal antibody” PMID 30536810 ↗ Dec 2018 |